Opdivo (nivolumab) Plus Chemotherapy Demonstrated Significant Overall and Progression-Free Survival Benefits Versus Chemotherapy in First-Line Treatment of Gastric and Esophageal Cancers
(WorldNews Japan)

Overall survival and progression-free survival benefit observed in patients whose tumors express PD-L1; overall survival benefit also observed in all-randomized population Efficacy benefit observed across patients with gastric cancer, gastroesophageal junction cancer or esophageal adenocarcinoma Primary results from Phase 3 CheckMate -649 trial featured in official Press Programme and selected for presentation during a Presidential Symposium at the European Society for Medical Oncology Virtual Congress 2020 PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced primary results from CheckMate -649, the pivotal Phase 3 trial in which first-line treatment with...